Skip to main content

Table 1 Patient characteristics and ventilation variables at enrolment

From: Strategies for lung- and diaphragm-protective ventilation in acute hypoxemic respiratory failure: a physiological trial

Age, median (IQR) 54 (49, 60)
Female sex, n (%) 10 (33)
APACHE II, median (IQR) 21 (18, 24)
SOFA, median (IQR) 11 (10, 12)
AHRF severity, median (IQR)  
 Moderate: PaO2:FiO2 100-200 mm Hg 7 (23)
 Severe: PaO2:FiO2 <100 mm Hg 23 (77)
Comorbidities, n (%)  
 COPD 5 (17)
 Asthma 3 (10)
 Diabetes 8 (27)
 Chronic kidney disease 1 (3)
 Interstitial lung disease 7 (23)
Etiology of respiratory failure  
 Bacterial pneumonia 13 (43)
 Fungal pneumonia 1 (3)
 Viral pneumonia (non-COVID-19) 2 (7)
 COVID-19 pneumonia 14 (47)
SAS, median (IQR) 1 (1,2)
PaO2:FiO2 (mm Hg)*, median (IQR) 109 (79, 167)
Ventilatory ratio†, median (IQR) 2 (1.6, 2.7)
Mode of ventilation, n (%)  
 Assist-control volume ventilation 21 (70)
 Assist-control pressure ventilation 9 (30)
VT/PBW (ml/kg), median (IQR) 6 (5, 8)
PEEP (cm H2O), median (IQR) 10 (9, 14)
Driving pressure (cm H2O), median (IQR) 17 (12, 19)
Respiratory system compliance (ml/cm H2O), median (IQR) 23 (16, 37)
Normalized respiratory system elastance (cm H2O/ml/PBW), median (IQR) 2.6 (1.9, 5)
ECLS blood flow, (L/min) median (IQR) 5 (4, 5)
Sweep gas flow (L/min), median (IQR) 5 (4, 5)
  1. IQR interquartile range, COPD chronic obstructive pulmonary disease, SOFA sequential organ failure assessment, SAS sedation-agitation score, VT tidal volume, PEEP positive end-expiratory pressure, PBW predicted body weight, ECLS extracorporeal life support
  2. *Represents only patients not receiving VV-ECMO (n = 14). Values of PaO2:FiO2 may not be representative of lung function in patients receiving VV-ECMO at enrolment
  3. Represents only patients not receiving VV-ECMO (n = 14). Values of VR may not be representative of lung function in patients receiving VV-ECMO at enrolment